Add to Watchlist
View Current for CAPR
View SuperFeed for CAPR
View Charts for CAPR
Add or remove $CAPR from your watchlists:
Hang tight! We're updating your watchlist data.
This might take a minute...
Capricor Therapeutics Inc
Health Care
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics… more
Thread Explorer
Explore popular threads around $CAPR
There are no threads for this stock
Go to Thread Explorer
Chart Explorer
Explore recent charts, graphs, and media
There are no charts for this stock
Latest News
Get the latest breaking news from the community
There is no recent news for this stock
Loading news, hang tight...
Google Search Trends - Past 12 months
Instantly visualize search trends for this specific symbol
Company Profile
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.Market Cap Type: Small